Evolus (EOLS) Competitors

$6.57 +0.07 (+1.08%)

Closing price 05/18/2026 04:00 PM Eastern

Extended Trading

$6.57 0.00 (0.00%)

As of 05/18/2026 07:41 PM Eastern

EOLS vs. ARDX, NUVB, AGIO, GLUE, and AMLX

Should you buy Evolus stock or one of its competitors? MarketBeat compares Evolus with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Evolus include Ardelyx (ARDX), Nuvation Bio (NUVB), Agios Pharmaceuticals (AGIO), Monte Rosa Therapeutics (GLUE), and Amylyx Pharmaceuticals (AMLX). These companies are all part of the "pharmaceutical products" industry.

How does Evolus compare to Ardelyx?

Ardelyx (NASDAQ:ARDX) and Evolus (NASDAQ:EOLS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, media sentiment, profitability, valuation and institutional ownership.

Ardelyx presently has a consensus target price of $15.70, indicating a potential upside of 156.96%. Evolus has a consensus target price of $16.00, indicating a potential upside of 143.53%. Given Ardelyx's stronger consensus rating and higher possible upside, analysts plainly believe Ardelyx is more favorable than Evolus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ardelyx	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
Evolus	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Evolus has lower revenue, but higher earnings than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than Evolus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ardelyx	$407.32M	3.71	-$61.60M	-$0.23	N/A
Evolus	$297.18M	1.46	-$51.64M	-$0.67	N/A

58.9% of Ardelyx shares are held by institutional investors. Comparatively, 90.7% of Evolus shares are held by institutional investors. 5.3% of Ardelyx shares are held by company insiders. Comparatively, 5.0% of Evolus shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Ardelyx has a net margin of -13.58% compared to Evolus' net margin of -14.39%. Evolus' return on equity of 0.00% beat Ardelyx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ardelyx	-13.58%	-38.11%	-11.85%
Evolus	-14.39%	N/A	-19.03%

Ardelyx has a beta of 0.62, suggesting that its stock price is 38% less volatile than the broader market. Comparatively, Evolus has a beta of 1.28, suggesting that its stock price is 28% more volatile than the broader market.

In the previous week, Ardelyx had 1 more articles in the media than Evolus. MarketBeat recorded 1 mentions for Ardelyx and 0 mentions for Evolus. Ardelyx's average media sentiment score of 1.70 beat Evolus' score of 1.67 indicating that Ardelyx is being referred to more favorably in the media.

Company	Overall Sentiment
Ardelyx	Very Positive
Evolus	Very Positive

Summary

Ardelyx beats Evolus on 12 of the 17 factors compared between the two stocks.

How does Evolus compare to Nuvation Bio?

Nuvation Bio (NYSE:NUVB) and Evolus (NASDAQ:EOLS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, media sentiment, valuation and risk.

Nuvation Bio has a beta of 1.51, indicating that its stock price is 51% more volatile than the broader market. Comparatively, Evolus has a beta of 1.28, indicating that its stock price is 28% more volatile than the broader market.

Nuvation Bio presently has a consensus target price of $12.50, indicating a potential upside of 196.56%. Evolus has a consensus target price of $16.00, indicating a potential upside of 143.53%. Given Nuvation Bio's stronger consensus rating and higher possible upside, research analysts clearly believe Nuvation Bio is more favorable than Evolus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvation Bio	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Evolus	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Evolus has higher revenue and earnings than Nuvation Bio. Evolus is trading at a lower price-to-earnings ratio than Nuvation Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvation Bio	$62.90M	23.33	-$204.63M	-$0.43	N/A
Evolus	$297.18M	1.46	-$51.64M	-$0.67	N/A

Evolus has a net margin of -14.39% compared to Nuvation Bio's net margin of -102.06%. Evolus' return on equity of 0.00% beat Nuvation Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvation Bio	-102.06%	-44.10%	-23.80%
Evolus	-14.39%	N/A	-19.03%

61.7% of Nuvation Bio shares are held by institutional investors. Comparatively, 90.7% of Evolus shares are held by institutional investors. 30.1% of Nuvation Bio shares are held by company insiders. Comparatively, 5.0% of Evolus shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Nuvation Bio had 4 more articles in the media than Evolus. MarketBeat recorded 4 mentions for Nuvation Bio and 0 mentions for Evolus. Evolus' average media sentiment score of 1.67 beat Nuvation Bio's score of 0.40 indicating that Evolus is being referred to more favorably in the news media.

Company	Overall Sentiment
Nuvation Bio	Neutral
Evolus	Very Positive

Summary

Nuvation Bio beats Evolus on 9 of the 16 factors compared between the two stocks.

How does Evolus compare to Agios Pharmaceuticals?

Evolus (NASDAQ:EOLS) and Agios Pharmaceuticals (NASDAQ:AGIO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

Evolus has a beta of 1.28, indicating that its share price is 28% more volatile than the broader market. Comparatively, Agios Pharmaceuticals has a beta of 0.58, indicating that its share price is 42% less volatile than the broader market.

Evolus has higher revenue and earnings than Agios Pharmaceuticals. Evolus is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evolus	$297.18M	1.46	-$51.64M	-$0.67	N/A
Agios Pharmaceuticals	$54.03M	31.05	-$412.78M	-$7.25	N/A

Evolus presently has a consensus target price of $16.00, indicating a potential upside of 143.53%. Agios Pharmaceuticals has a consensus target price of $41.56, indicating a potential upside of 47.31%. Given Evolus' stronger consensus rating and higher possible upside, research analysts plainly believe Evolus is more favorable than Agios Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evolus	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Agios Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

Evolus has a net margin of -14.39% compared to Agios Pharmaceuticals' net margin of -639.84%. Evolus' return on equity of 0.00% beat Agios Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evolus	-14.39%	N/A	-19.03%
Agios Pharmaceuticals	-639.84%	-34.11%	-31.66%

In the previous week, Agios Pharmaceuticals had 5 more articles in the media than Evolus. MarketBeat recorded 5 mentions for Agios Pharmaceuticals and 0 mentions for Evolus. Evolus' average media sentiment score of 1.67 beat Agios Pharmaceuticals' score of 0.64 indicating that Evolus is being referred to more favorably in the media.

Company	Overall Sentiment
Evolus	Very Positive
Agios Pharmaceuticals	Positive

90.7% of Evolus shares are owned by institutional investors. 5.0% of Evolus shares are owned by company insiders. Comparatively, 5.4% of Agios Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Evolus beats Agios Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Evolus compare to Monte Rosa Therapeutics?

Monte Rosa Therapeutics (NASDAQ:GLUE) and Evolus (NASDAQ:EOLS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, earnings, profitability and analyst recommendations.

Evolus has a net margin of -14.39% compared to Monte Rosa Therapeutics' net margin of -302.69%. Evolus' return on equity of 0.00% beat Monte Rosa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monte Rosa Therapeutics	-302.69%	-40.99%	-25.94%
Evolus	-14.39%	N/A	-19.03%

Monte Rosa Therapeutics currently has a consensus target price of $32.50, suggesting a potential upside of 80.46%. Evolus has a consensus target price of $16.00, suggesting a potential upside of 143.53%. Given Evolus' higher probable upside, analysts plainly believe Evolus is more favorable than Monte Rosa Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monte Rosa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Evolus	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

80.0% of Monte Rosa Therapeutics shares are held by institutional investors. Comparatively, 90.7% of Evolus shares are held by institutional investors. 6.4% of Monte Rosa Therapeutics shares are held by company insiders. Comparatively, 5.0% of Evolus shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Monte Rosa Therapeutics has higher earnings, but lower revenue than Evolus. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than Evolus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monte Rosa Therapeutics	$123.67M	12.30	-$38.63M	-$1.48	N/A
Evolus	$297.18M	1.46	-$51.64M	-$0.67	N/A

In the previous week, Monte Rosa Therapeutics had 2 more articles in the media than Evolus. MarketBeat recorded 2 mentions for Monte Rosa Therapeutics and 0 mentions for Evolus. Evolus' average media sentiment score of 1.67 beat Monte Rosa Therapeutics' score of 1.17 indicating that Evolus is being referred to more favorably in the news media.

Company	Overall Sentiment
Monte Rosa Therapeutics	Positive
Evolus	Very Positive

Monte Rosa Therapeutics has a beta of 1.62, suggesting that its share price is 62% more volatile than the broader market. Comparatively, Evolus has a beta of 1.28, suggesting that its share price is 28% more volatile than the broader market.

Summary

Evolus beats Monte Rosa Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Evolus compare to Amylyx Pharmaceuticals?

Amylyx Pharmaceuticals (NASDAQ:AMLX) and Evolus (NASDAQ:EOLS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, earnings, profitability and analyst recommendations.

Amylyx Pharmaceuticals has a net margin of 0.00% compared to Evolus' net margin of -14.39%. Evolus' return on equity of 0.00% beat Amylyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amylyx Pharmaceuticals	N/A	-55.69%	-50.73%
Evolus	-14.39%	N/A	-19.03%

In the previous week, Amylyx Pharmaceuticals had 11 more articles in the media than Evolus. MarketBeat recorded 11 mentions for Amylyx Pharmaceuticals and 0 mentions for Evolus. Evolus' average media sentiment score of 1.67 beat Amylyx Pharmaceuticals' score of 0.05 indicating that Evolus is being referred to more favorably in the news media.

Company	Overall Sentiment
Amylyx Pharmaceuticals	Neutral
Evolus	Very Positive

Evolus has higher revenue and earnings than Amylyx Pharmaceuticals. Evolus is trading at a lower price-to-earnings ratio than Amylyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amylyx Pharmaceuticals	$87.37M	16.37	-$144.74M	-$1.50	N/A
Evolus	$297.18M	1.46	-$51.64M	-$0.67	N/A

Amylyx Pharmaceuticals currently has a consensus target price of $23.00, suggesting a potential upside of 78.85%. Evolus has a consensus target price of $16.00, suggesting a potential upside of 143.53%. Given Evolus' higher probable upside, analysts plainly believe Evolus is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amylyx Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
Evolus	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. Comparatively, 90.7% of Evolus shares are held by institutional investors. 12.3% of Amylyx Pharmaceuticals shares are held by company insiders. Comparatively, 5.0% of Evolus shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Amylyx Pharmaceuticals has a beta of -0.11, suggesting that its share price is 111% less volatile than the broader market. Comparatively, Evolus has a beta of 1.28, suggesting that its share price is 28% more volatile than the broader market.

Summary

Amylyx Pharmaceuticals beats Evolus on 9 of the 17 factors compared between the two stocks.

Get Evolus News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EOLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EOLS vs. The Competition

Export

Metric	Evolus	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$428.06M	$8.09B	$6.25B	$12.29B
Dividend Yield	N/A	2.54%	2.80%	5.30%
P/E Ratio	-9.81	16.00	20.86	25.23
Price / Sales	1.46	8.14	549.88	74.61
Price / Cash	N/A	16.74	27.48	37.30
Price / Book	-18.25	3.58	9.67	6.63
Net Income	-$51.64M	$224.05M	$3.56B	$335.59M
7 Day Performance	1.08%	-2.35%	-1.71%	-1.20%
1 Month Performance	40.09%	-3.00%	-2.67%	-1.16%
1 Year Performance	-33.64%	0.66%	30.01%	28.10%

Evolus Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EOLS Evolus	2.8418 of 5 stars	$6.57 +1.1%	$16.00 +143.5%	-32.3%	$428.06M	$297.18M	N/A	170	Positive News
ARDX Ardelyx	4.3052 of 5 stars	$6.61 -2.5%	$15.70 +137.5%	+57.5%	$1.67B	$407.32M	N/A	90
NUVB Nuvation Bio	2.9102 of 5 stars	$4.77 -0.5%	$12.50 +162.3%	+86.9%	$1.66B	$143.05M	N/A	60
AGIO Agios Pharmaceuticals	3.0851 of 5 stars	$27.99 +0.7%	$41.56 +48.5%	-3.3%	$1.65B	$54.03M	N/A	390	Positive News
GLUE Monte Rosa Therapeutics	2.6133 of 5 stars	$20.26 +4.5%	$32.50 +60.4%	+352.5%	$1.64B	$123.67M	N/A	90	Negative News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EOLS) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Evolus (EOLS) Competitors

EOLS vs. ARDX, NUVB, AGIO, GLUE, and AMLX

How does Evolus compare to Ardelyx?

Summary

How does Evolus compare to Nuvation Bio?

Summary

How does Evolus compare to Agios Pharmaceuticals?

Summary

How does Evolus compare to Monte Rosa Therapeutics?

Summary

How does Evolus compare to Amylyx Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EOLS vs. The Competition

Evolus Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Evolus (EOLS) Competitors

EOLS vs. ARDX, NUVB, AGIO, GLUE, and AMLX

How does Evolus compare to Ardelyx?

Do analysts recommend ARDX or EOLS?

Which has higher valuation and earnings, ARDX or EOLS?

Do institutionals & insiders have more ownership in ARDX or EOLS?

Is ARDX or EOLS more profitable?

Which has more volatility & risk, ARDX or EOLS?

Does the media refer more to ARDX or EOLS?

Summary

How does Evolus compare to Nuvation Bio?

Which has more risk and volatility, NUVB or EOLS?

Do analysts recommend NUVB or EOLS?

Which has better valuation and earnings, NUVB or EOLS?

Is NUVB or EOLS more profitable?

Do institutionals and insiders believe in NUVB or EOLS?

Does the media favor NUVB or EOLS?

Summary

How does Evolus compare to Agios Pharmaceuticals?

Which has more volatility & risk, EOLS or AGIO?

Which has better valuation and earnings, EOLS or AGIO?

Do analysts rate EOLS or AGIO?

Is EOLS or AGIO more profitable?

Does the media prefer EOLS or AGIO?

Do insiders and institutionals have more ownership in EOLS or AGIO?

Summary

How does Evolus compare to Monte Rosa Therapeutics?

Is GLUE or EOLS more profitable?

Do analysts rate GLUE or EOLS?

Do insiders & institutionals believe in GLUE or EOLS?

Which has higher valuation and earnings, GLUE or EOLS?

Does the media prefer GLUE or EOLS?

Which has more volatility and risk, GLUE or EOLS?

Summary

How does Evolus compare to Amylyx Pharmaceuticals?

Is AMLX or EOLS more profitable?

Does the media prefer AMLX or EOLS?

Which has higher valuation and earnings, AMLX or EOLS?

Do analysts rate AMLX or EOLS?

Do insiders & institutionals believe in AMLX or EOLS?

Which has more volatility and risk, AMLX or EOLS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EOLS vs. The Competition

Evolus Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools